Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team.
| Autor: | Ignoffo, Robert J, Knapp, Katherine K, Seung, Amy, Brown, Victoria, Hough, Shannon, Rieband, Grazyna, Dang, Thu Oanh, Palumbo, Alison, Urmanski, Angela |
|---|---|
| Předmět: |
OUTPATIENT medical care
ONCOLOGY nursing CANCER patients CANCER patient medical care COMMUNITIES HEALTH care teams HOSPITAL medical staff WORKING hours IMMUNOTHERAPY INTERNSHIP programs INTERPROFESSIONAL relations INTERVIEWING LABOR supply LEADERSHIP MEDICAL appointments MEDICAL care NURSE practitioners PATIENT education PHYSICIANS POPULATION geography JOB qualifications GRADUATE nursing education HEALTH insurance reimbursement OCCUPATIONAL roles THEMATIC analysis MASTERS programs (Higher education) DESCRIPTIVE statistics |
| Zdroj: | Journal of Oncology Pharmacy Practice; Jan2021, Vol. 27 Issue 1, p5-13, 9p |
| Abstrakt: | Objective: The purpose of this study was to identify trends in oncology care that allow one to forecast workforce supply and demand, the training and skills needed by the oncology pharmacist for the likely future of oncology care. Methods: Interviews were conducted with experienced oncology pharmacists in leadership roles at 20 organizations balanced by geographic region and type of practice site (academic or community/ambulatory). Results were analyzed using descriptive statistics and theme identification. Results: Practice sites differed widely in numbers of patient visits, practitioner/patient ratios, residency program presence, and other structural features. Despite this, the majority reported an expectation of growth in cancer patients, oncology physicians, oncology pharmacists, pharmacy technicians, oncology nurses, and advanced practice practitioners in the next two to five years. Fifty percent of sites currently support Post Graduate Year 2 (PGY2) oncology residencies. At least 50% reported routine pharmacist involvement in 12 clinical functions. More future involvement was predicted for immunotherapy (80%) and oral oncolytic therapy (90%). Interprofessional involvement was reported for a broad variety of practice-related committees and patient education teams. Limited pharmacist involvement in credentialing, quality measurement, and value-based reimbursement systems was found. Conclusion: Anticipated increases in demand for oncology pharmacists strongly suggest the need for more PGY2 oncology residency programs and on-the-job oncology training programs. Oncology pharmacists are currently involved in many clinical and administrative functions including multidisciplinary management. While a core set of clinical functions has been identified, oncology pharmacists must prepare for the increased use of oral oncology agents and immunotherapy. Pharmacist involvement in value-based reimbursement and other data-based quality outcome measurements should be increased to optimize involvement in team-based patient care. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|